Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

4SC AG Further Strengthens Supervisory Board

Published: Monday, December 31, 2012
Last Updated: Monday, December 31, 2012
Bookmark and Share
Appointment of Dr Irina Antonijevic and Mr Klaus Kühn.

4SC AG has announced the appointment of Dr Irina Antonijevic and Mr Klaus Kühn to the company's Supervisory Board.

In a by-election at Annual General Meeting of 4SC AG, Dr Antonijevic and Mr Kühn were elected to the Supervisory Board for the remaining term of Dr Jörg Neermann and Mr Günter Frankenne, who have stepped down from the Supervisory Board.

The terms of office will run until the end of the Annual General Meeting that resolves on formally approving the actions of the Supervisory Board for financial year 2012.

Dr Antonijevic, Director Clinical Research at US pharmaceutical company Sanofi, has many years of international experience in clinical drug development and extensive expertise gained in executive positions both in the pharmaceutical industry and in medical research in a university environment.

Klaus Kühn, former Chief Financial Officer of Bayer AG (2002 to 2010), has more than 30 years of experience in executive positions primarily in the chemical and pharmaceutical industry with a focus on finance and accounting.

The shareholders of 4SC AG also approved all of the resolutions proposed to the Annual General Meeting by the Management Board and the Supervisory Board with the required majority, including the following items:
• Resolution on the approval of the remuneration system for members of the Management Board;
• Approval of a control and profit transfer agreement between 4SC AG and 4SC Discovery GmbH;
• Resolution on the creation of new Authorized Capital, adjusted to the share capital that was raised following the capital increase in June 2012;
• Resolution on a new authorization of the Management Board to issue convertible bonds, bonds with warrants, profit participation rights and/or income debentures and create corresponding Conditional Capital.

A total of 78.3% of the voting capital was represented at the 2012 Annual General Meeting of 4SC AG.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Strengthens Patent Protection for Lead Cancer Compound Resminostat
US patent for medical use in cancer and Canadian composition of matter patent granted.
Wednesday, July 01, 2015
BEYOND RESEARCH Initiative of 4SC Discovery and CRELUX Reaches First Milestone
Compounds for inhibiting oxygen radicals and associated signalling pathways optimized for developing innovative therapies for degenerative diseases.
Tuesday, January 13, 2015
4SC Discovery Receives EU Grant Worth EUR 450,000
Three-year research collaboration with the Medical Clinic of the University of Munich includes a project for identification and optimization of new compounds against a novel epigenetic target molecule.
Thursday, April 17, 2014
4SC Announces Financial Results for a Successful Year 2012
Consolidated results considerably improved due to rising revenue and reduced costs.
Tuesday, March 26, 2013
4SC's Successful Development Continues in Third Quarter of 2012
Consolidated financial results improved in third quarter and first nine months.
Friday, November 09, 2012
4SC Announces Financial Results for the First Quarter of 2012
Company has made a successful start to 2012.
Monday, October 22, 2012
4SC Receives Milestone Payment from Research Collaboration with SKK
4SC had contributed its know-how in the field of medicinal chemistry to investigate new classes of substances for the potential therapy of metabolic diseases.
Monday, October 15, 2012
4SC Discovery, Crelux and Ribological Launch Collaboration
Collaboration for the discovery and optimization of new anti-cancer drugs.
Tuesday, July 17, 2012
4SC's Vidofludimus Shows Preclinical Evidence in a Kidney Transplantation Model
New preclinical data published in peer-reviewed article in Transplantation.
Tuesday, June 19, 2012
4SC AG Announces Election of Dr Thomas Werner to Chairman of the Supervisory Board
Company also elected Dr Manfred Rüdiger as its new deputy chairman.
Thursday, June 14, 2012
4SC's Partner Yakult Honsha Starts Clinical Development with Cancer Compound Resminostat in Japan
The Phase I study will assess safety of resminostat in Japanese patients, which is a prerequisite of the drug's further late-stage clinical development in Japan.
Monday, May 21, 2012
4SC Discovery and CRELUX Enter into a Strategic Alliance
Strategic partnership for integrated drug discovery services.
Monday, April 23, 2012
4SC to Present at Two Upcoming Investor Conferences
Future leaders in the Biotech Industry conference, 20 April 2012 in New York.
Tuesday, April 17, 2012
Henkel and 4SC Discovery Start Research Collaboration in Compound Screening
Aim is to identify new and more effective laundry detergent ingredients.
Monday, April 09, 2012
4SC’s Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation
European Medicines Agency recommend resminostat as orphan medicinal product for the treatment of Hodgkin’s Lymphoma.
Friday, October 14, 2011
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos